<DOC>
	<DOCNO>NCT02675829</DOCNO>
	<brief_summary>The purpose study find effect , drug call ado-trastuzumab emtansine patient cancer think control abnormal HER2 gene .</brief_summary>
	<brief_title>Trial Ado-Trastuzumab Emtansine Patients With HER2 Amplified Mutant Cancers</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Men woman ≥18 year old . Pathologically confirm advanced solid tumor cancer For Cohort 1 , document activate HER2 mutation lung cancer CLIA laboratory , specifically exon 20 insYVMA ( Y772_A775dup ) , insGSP ( G778_P780dup ) , insTGT ( G776delinsVC ) , single base pair substitution L755A , L755S , V777L , V659E , S310F , another HER2 mutation approve Principal Investigator For Cohorts 2 , 3 , 4 , document HER2 amplification identify next generation sequence MSKIMPACT another Clinical Laboratory Improvement Amendments ( CLIA ) laboratory , document HER2 amplification insitu hybridization ( ISH ) HER2/CEP17 ratio ≥2.0 CLIA laboratory Measurable evaluable indicator lesion ( ) define RECIST v1.1 . Patients without RECIST measurable disease eligible enrollment `` Other '' cohort provide disease evaluate use another accept response criterion ( e.g . Gynecologic Cancer InterGroup ( GCIG ) CA125 Response Criteria , PET Response Criteria Solid Tumors ( PERCIST ) . Karnofsky Performance Status 70 % . Left ventricular ejection fraction ( LVEF ) ≥50 % measure echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) . Negative βhuman chorionic gonadotropin ( hCG ) pregnancy test within 2 week enrollment premenopausal woman reproductive capacity woman less 12 month menopause . Pregnancy screen conduct woman age 50 year per institutional standard . Women child bear potential must agree use highly effective method contraception time inform consent 6 month last dose adotrastuzumab emtansine . Men must agree use barrier method contraception treatment 6 month last dose adotrastuzumab emtansine . Absolute neutrophil count ≥ 1,000/µL within 30 day prior C1D1 Platelet count ≥ 100,000/µL within 30 day prior C1D1 Total bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) , case Gilbert 's syndrome , ≤ 2x ULN within 30 day prior C1D1 Aspartate aminotransferase and/or alanine aminotransferase ≤ 3 x ULN ( ≤ 5 x ULN liver metastasis present ) within 30 day prior C1D1 Provide write , inform consent participate study follow study procedure Prior therapy result cumulative epirubicin dose ≥ 900mg/m2 cumulative doxorubicin dose ≥ 500mg/m2 equivalent dose another anthracycline . Prior therapy adotrastuzumab emtansine ( patient prior trastuzumab HER2 target agent eligible ) . Symptomatic congestive heart failure ( New York Heart Association Classification IIIV ) . Myocardial infarction unstable angina within 6 month enrollment . Unstable ventricular arrhythmia require treatment . Grade 3 bad peripheral neuropathy define CTCAE v4.1 . Women pregnant breastfeeding . Known hypersensitivity component adotrastuzumab emtansine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HER2 mutant</keyword>
	<keyword>HER2 amplify</keyword>
	<keyword>Ado-Trastuzumab Emtansine</keyword>
	<keyword>15-335</keyword>
</DOC>